Carcinoembryonic antigen (CEA) is a tumor marker for the most common forms of
adenocarcinomas. We have previously described C57BL/6 mice transgenic for the complete …

Several cancer vaccine efforts have been directed to simultaneously cotarget multiple tumor
antigens, with the intent to achieve broader immune responses and more effective control of …

Carcinoembryonic antigen (CEA), a glycosylated protein of Mr 180, is one of the most widely
studied oncofetal antigens. A majority of gastrointestinal cancers as well as breast and non …

Carcinoembryonic antigen (CEA) is a non-specific serum biomarker that is elevated in
various malignancies such as colorectal cancer, medullary thyroid cancer, breast cancer …

Carcinoembryonic antigen (CEA) is a well-characterized oncofetal glycoprotein whose
overexpression by human adenocarcinomas has been a target for cancer immunotherapy …

Humans have a sophisticated immune system that functions to clear invading organisms
and abnormal cells. However, cancers are able to arise despite this immune system …

Carcinoembryonic antigen (CEA) is a tumor-associated antigen targeted for the
development of colorectal tumor vaccines. In this study, we developed papillomavirus …

The vaccine approach to cancer therapy is still in the early stages. Since any immune
response has a limited capacity, immunotherapeutic manipulations to destroy tumor will …

Continuing advances in immunology and molecular biology during the past several decades
have provided optimism that immunomodulatory strategies may be clinically useful in …

Colorectal cancer (CRC) is a common cancer in the world and also has a high death rate. It
is reported that vaccination is a great strategy for CRC. CRC vaccines are based on CRC …